DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

INCY·Incyte Corporation

$.
-. (-.%)
After Hours
High
$118.67
Open
$118.53
Market Cap
23.12B
52W High
$118.97
Low
$115.21
P. Close
$116.72
P/E
16.15
52W Low
$67.17
Fwd P/E
13.83
DailyIQ Est.
$115.04
Technical Score (1D)
82
BUY
News Sentiment
78
BULLISH
The company has announced its second‑quarter earnings call for July 28 at 8:00 a.m. ET, with no guidance yet released. This call will be the first opportunity for investors to see updated revenue, operating results and pipeline progress, so traders should focus on the call’s details and the accompanying press release. In the first quarter, Jakafi sales rose 7 % YoY and Opzelura sales climbed 20 % YoY, while total revenue increased 21 % to $1.27 billion and EPS jumped 83.7 %. The strong cash flow from these drugs underpins the company’s expansion plans in dermatology and oncology, suggesting a positive trajectory for the next 1–10 trading days. RBC Capital upgraded Incyte to a Sector Perform rating and lifted its price target to $99, reflecting confidence in the pipeline and recent commercial traction. The upgrade may reinforce bullish sentiment, so traders should monitor the Q2 earnings call and any subsequent guidance for confirmation. The completed acquisition of Vega Therapeutics adds several hematology candidates, including a Phase 3 monoclonal antibody for von Willebrand disease, broadening the company’s late‑stage portfolio. This diversification could accelerate future revenue streams, so watch for clinical development milestones and potential partnership announcements. Positive regulatory updates for Opzelura—including a favorable EU CHMP opinion and a potential CMS settlement—could open new markets, so keep an eye on FDA guidance, sales data, and CMS decisions.
Earnings Summary
Incyte Corporation, a biopharmaceutical company focused on developing therapies for myelofibrosis, lymphoma, and other conditions, operates across the United States, Europe, Canada, and Japan, positioning it within the biotechnology sector. Recent quarterly performance shows that Incyte’s Q4 2025 EPS of $1.80 beat the $1.57 estimate while revenue of $1.507 billion exceeded the $1.251 billion estimate, and Q1 2026 EPS of $1.81 surpassed the $1.34 estimate with revenue of $1.273 billion versus a $1.211 billion estimate; compared to the prior two quarters (Q2 2025 EPS $1.57, revenue $1.216 billion and Q3 2025 EPS $2.26, revenue $1.366 billion), the company maintained earnings beats but experienced a decline in EPS from Q3 to Q1, while revenue grew in Q4 but fell in Q1. Historically, Incyte has consistently outperformed analyst expectations, with four of the last five quarters reporting EPS above estimates and revenue growth in each of the most recent quarters, indicating a robust earnings trajectory despite occasional revenue dips. Recent news highlights the acquisition of Vega Therapeutics, adding a Phase 3 monoclonal antibody for von Willebrand disease and expanding the company’s hematology pipeline, as well as regulatory momentum for Opzelura, which received a positive CHMP opinion for EU approval, potentially opening a new revenue stream in atopic dermatitis; these developments reinforce Incyte’s diversified portfolio and suggest near‑term catalysts for growth. Forward‑looking watch points for investors include monitoring the next earnings release for guidance updates on the Vega integration timeline, early EU sales data for Opzelura, and any partnership or licensing announcements that could accelerate commercialization, as well as tracking regulatory decisions that may impact the company’s product pipeline and overall valuation trajectory.

EPS

EstBeatMiss
$0.85$1.25$1.65$2.05$2.44Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.97 - -
Q1'26$1.34$1.81+35.1%
Q4'25$1.57$1.80+14.8%
Q3'25$1.64$2.26+38.0%
Q2'25$1.47$1.57+6.6%
Q1'25$1.03$1.16+12.3%

Revenue

EstBeatMiss
$985M$1.1B$1.3B$1.4B$1.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.4B - -
Q1'26$1.2B$1.3B+5.1%
Q4'25$1.3B$1.5B+20.5%
Q3'25 - $1.4B -
Q2'25 - $1.2B -
Q1'25 - $1.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

INCY Stock Snapshot

INCY is currently trading at $116.60, giving Incyte Corporation a market cap of 23.12B and a P/E ratio of 16.1. Today's range spans $115.21–$118.67, with shares opening at $118.53 and moving down $0.12 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 78/100.

Over the past year INCY has traded between $67.17 and $118.97 - the current price is +73.6% off the 52-week low and -2.0% from the high. 35 analysts cover the stock with a Hold consensus and a mean 12-month target of $111.45 (range $71.00–$140.00), implying downside of -4.4%.

What INCY has right now - BUY signal, 82/100 technical score, bullish sentiment at 78/100, price $116.60 (near 52-week highs) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 16.1) At 23.12B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $67.17–$118.97.

What makes INCY's BUY setup (82/100) particularly actionable at 23.12B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $116.60 (near 52-week highs in $67.17–$118.97), with sentiment running bullish at 78/100, the setup rewards conviction-sized positioning more than it does speculative small bets.